Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kerry Lynn Reynolds, M.D.

Co-Author

This page shows the publications co-authored by Kerry Reynolds and Alexander Faje.
Connection Strength

1.221
  1. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.239
  2. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522.
    View in: PubMed
    Score: 0.232
  3. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019 Nov 21.
    View in: PubMed
    Score: 0.211
  4. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404.
    View in: PubMed
    Score: 0.211
  5. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019 Sep; 181(3):211-219.
    View in: PubMed
    Score: 0.208
  6. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant. 2021 12 02; 36(12):2241-2247.
    View in: PubMed
    Score: 0.061
  7. The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients. Ann Oncol. 2021 08; 32(8):1050-1051.
    View in: PubMed
    Score: 0.059
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.